May 2024 $3 M Private placement after listing $2 to $10 million 4
BioSig Technologies, Inc.: Private sale, May 2024 × Investors in this round 4 investors had bought by the notice of Jun 6, 2024: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $240,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Anthony Amato · Executive Officer, Director · Chief Executive Officer Frederick D. Hrkac · Executive Officer, Director · Acting Chief Financial Officer Chris F. Baer · Director Donald F. Browne · Director Steven E. Abelman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co. (CRD 000000375) · New York, New York Sold in CA, IL, and outside the US Remarks in the notice On fees: “"H.C. Wainwright & Co. (""HCW"") acted as exclusive placement agent for the offering. HCW received a cash fee equal to 7.0% of the gross proceeds of the offering and a management fee equal to 1.0% of the gross proceeds raised in the offering."”On the amounts: “Represents total gross proceeds received by the company in connection with a registered direct offering of shares of common stock and a concurrent private placement of common stock purchase warrants.”Signed by Anthony Amato, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 6, 2024. Read the notice at the SEC .
options SEC May 2024 $1 M Private placement after listing Under $2 million 6
BioSig Technologies, Inc.: Private sale, May 2024 × Investors in this round 6 investors had bought by the notice of Jun 6, 2024: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anthony Amato · Executive Officer, Director · Chief Executive Officer Frederick D. Hrkac · Executive Officer · Acting Chief Financial Officer Chris F. Baer · Director Donald F. Browne · Director Steven E. Abelman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold 783,406 shares of common stock at a purchase price of $1.4605 per share and warrants to purchase up to 391,703 shares at an exercise price of $1.398 per share. $509,165 of the purchase price was paid by the conversion of an outstanding note.”Signed by Anthony Amato, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 6, 2024. Read the notice at the SEC .
equity, options SEC Jan 2024 $1 M Private placement after listing Under $2 million 7
BioSig Technologies, Inc.: Private sale, Jan 2024 × Investors in this round 7 investors had bought by the notice of Jan 16, 2024: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold 2,607,170 shares at a purchase price of $0.3989 per share and warrants to purchase up to 1,303,585 shares at an exercise price of $0.3364 per share. Amount includes $438,525.99 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 16, 2024. Read the notice at the SEC .
equity, options SEC Sep 2023 $1 M Private placement after listing Under $2 million 10
BioSig Technologies, Inc.: Private sale, Sep 2023 × Investors in this round 10 investors had bought by the notice of Oct 6, 2023: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $30,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in OH Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 40,511 shares of common stock.”On the amounts: “Issuer sold 1,458,770 shares at a purchase price of $0.5554 per share and warrants to purchase up to 729,385 shares at an exercise price of $0.4929 per share. Amount includes $359,513.87 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 6, 2023. Read the notice at the SEC .
equity, options SEC Jul 2023 $2 M Private placement after listing $2 to $10 million 1
BioSig Technologies, Inc.: Private sale, Jul 2023 × Investors in this round 1 investor had bought by the notice of Aug 1, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $150,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in OH Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 110,072 shares of common stock.”On the amounts: “Issuer sold 1,467,624 shares at a purchase price of $1.02206 per share and warrants to purchase up to 733,812 shares at an exercise price of $0.95956 per share. Amount includes $704,136.64 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 1, 2023. Read the notice at the SEC .
equity, options SEC May 2023 $4 M Private placement after listing $2 to $10 million 20
BioSig Technologies, Inc.: Private sale, May 2023 × Investors in this round 20 investors had bought by the notice of May 26, 2023: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $104,617
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in FL, IL, OH, PA Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 62,698 shares of common stock.”On the amounts: “Issuer sold 1,798,452 shares at a purchase price of $1.3905 per share and warrants to purchase up to 899,226 shares at an exercise price of $1.328 per share. Amount includes $1,194,172.13 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed May 26, 2023. Read the notice at the SEC .
equity, options SEC Apr 2023 $1 M Private placement after listing Under $2 million 14
BioSig Technologies, Inc.: Private sale, Apr 2023 × Investors in this round 14 investors had bought by the notice of Apr 28, 2023: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $11,250
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in no state named, and outside the US Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 7,862 shares of common stock.”On the amounts: “Issuer sold 792,454 shares at a purchase price of $1.1925 per share and warrants to purchase up to 396,227 shares at an exercise price of $1.13 per share. Amount includes $447,736.51 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 28, 2023. Read the notice at the SEC .
equity, options SEC Mar 2023 $2 M Private placement after listing Under $2 million 5
BioSig Technologies, Inc.: Private sale, Mar 2023 × Investors in this round 5 investors had bought by the notice of Apr 5, 2023: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $64,610
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in OH Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 49,465 shares of common stock.”On the amounts: “Issuer sold 935,130 shares at a purchase price of $1.0885 per share and warrants to purchase up to 467,565 shares at an exercise price of $1.026 per share. Amount includes $479,721.69 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 5, 2023. Read the notice at the SEC .
equity, options SEC Mar 2023 $3 M Private placement after listing $2 to $10 million 17
BioSig Technologies, Inc.: Private sale, Mar 2023 × Investors in this round 17 investors had bought by the notice of Mar 20, 2023: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $150,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in OH Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 67,611 shares of common stock.”On the amounts: “Issuer sold 1,550,540 shares at a purchase price of $1.10928 per share and warrants to purchase up to 775,270 shares at an exercise price of $1.04678 per share. Amount includes $811,537 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 20, 2023. Read the notice at the SEC .
equity, options SEC Feb 2023 $2 M Private placement after listing $2 to $10 million 7
BioSig Technologies, Inc.: Private sale, Feb 2023 × Investors in this round 7 investors had bought by the notice of Feb 13, 2023: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $80,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J Buhaly · Executive Officer · Chief Financial Officer David J Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in NV Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 87,331 shares of common stock.”On the amounts: “Issuer sold 1,591,750 shares at a purchase price of $0.8588 per share and warrants to purchase up to 795,875 shares at an exercise price of $0.7963 per share. Amount includes $633,755 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 13, 2023. Read the notice at the SEC .
equity, options SEC Jan 2023 $2 M Private placement after listing Under $2 million 1
BioSig Technologies, Inc.: Private sale, Jan 2023 × Investors in this round 1 investor had bought by the notice of Jan 31, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $104,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steve L. Chaussy · Executive Officer · Chief Financial Officer David L. Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in OH Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 124,904 shares of common stock.”On the amounts: “Issuer sold 1,665,384 shares at a purchase price of $0.7806 per share and warrants to purchase up to 832,692 shares at an exercise price of $0.7181 per share. Amount includes $597,956 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 31, 2023. Read the notice at the SEC .
equity, options SEC Jan 2023 $2 M Private placement after listing Under $2 million 17
BioSig Technologies, Inc.: Private sale, Jan 2023 × Investors in this round 17 investors had bought by the notice of Feb 13, 2023: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $43,760
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steven J. Buhaly · Executive Officer · Chief Financial Officer David L. Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in CA, OH, PA, TX Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 71,214 shares of common stock.”On the amounts: “Issuer sold an aggregate of 2,178,316 shares at a purchase price of $0.57608 per share and warrants to purchase up to 1,809,158 shares at an exercise price of $0.51358 per share. Amount includes $559,370 that may be received upon exercise of the warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 13, 2023. Read the notice at the SEC .
equity, options SEC Dec 2022 $1 M Private placement after listing Under $2 million 8
BioSig Technologies, Inc.: Private sale, Dec 2022 × Investors in this round 8 investors had bought by the notice of Jan 4, 2023: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $40,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steve L. Chaussy · Executive Officer · Chief Financial Officer David L. Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in OH Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 49,213 shares of common stock.”On the amounts: “Issuer sold 2,161,598 shares of common stock and warrants to purchase up to 1,080,799 shares of common stock at a combined purchase price of $0.508 per share and accompanying warrant. The amount doesn't include proceeds from the exercise of such warrants.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 4, 2023. Read the notice at the SEC .
equity, options SEC Nov 2022 $1 M Private placement after listing Under $2 million 10
BioSig Technologies, Inc.: Private sale, Nov 2022 × Investors in this round 10 investors had bought by the notice of Dec 30, 2022: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $40,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John L. Sieckhaus · Executive Officer · Chief Operating Officer Kenneth L. Londoner · Executive Officer, Director · Chairman and Chief Executive Officer Michael Graydon Fleming, Jr. · Executive Officer · Chief Commercial Officer Steve L. Chaussy · Executive Officer · Chief Financial Officer David L. Weild IV · Director Donald E. Foley · Director Frederick D. Hrkac · Director James J. Barry · Director James L. Klein · Director Patrick J. Gallagher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · Boca Raton, Florida Sold in OH Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 60,976 shares of common stock.”On the amounts: “The issuer sold an aggregate of 3,541,469 shares of common stock at $0.41 per share to certain accredited investors.”Signed by Kenneth L. Londoner, Chairman and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 30, 2022. Read the notice at the SEC .
equity SEC Aug 2019 $3 M Private placement after listing $2 to $10 million 17
BioSig Technologies, Inc.: Private sale, Aug 2019 × Investors in this round 17 investors had bought by the notice of Aug 20, 2019: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $4 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer Steve Chaussy · Executive Officer · Chief Financial Officer Andrew Filler · Director David Weild · Director Donald Foley · Director Jeffrey O'Donnell · Director Jerome Zeldis · Director Patrick Gallagher · Director Samuel Navarro · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 20, 2019. Read the notice at the SEC .
equity SEC Mar 2019 $9 M Private placement after listing $2 to $10 million 103
BioSig Technologies, Inc.: Private sale, Mar 2019 × Investors in this round 103 investors had bought by the notice of Mar 28, 2019: 103 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $9 M of $9 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer Steve Chaussy · Executive Officer · Chief Financial Officer Andrew Filler · Director David Weild · Director Donald Foley · Director Jeffrey ODonnell · Director Patrick Gallagher · Director Roy Tanaka · Director Seth Fischer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Steve Chaussy, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 28, 2019. Read the notice at the SEC .
equity SEC Aug 2018 $4 M Private placement after listing $2 to $10 million 72
BioSig Technologies, Inc.: Private sale, Aug 2018 × Investors in this round 72 investors had bought by the notice of Aug 28, 2018: 72 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $10 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $150,035
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer Steve Chaussy · Executive Officer · Chief Financial Officer Andrew Filler · Director David Weild · Director Donald Foley · Director Jeffrey O'Donnell · Director Patrick Gallagher · Director Roy Tanaka · Director Seth Fischer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in AR, CA, CT, FL, GA, IL, MA, MD, MN, NJ, NV, NY, TX, WA Remarks in the notice On fees: “Laidlaw is also entitled to warrants to purchase up to 285,172 shares of the Company's common stock.”Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 28, 2018. Read the notice at the SEC .
equity, options SEC Feb 2018 $2 M Private placement after listing Under $2 million 2
BioSig Technologies, Inc.: Private sale, Feb 2018 × Investors in this round 2 investors had bought by the notice of Feb 27, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer Steve Chaussy · Executive Officer · Chief Financial Officer Andrew Filler · Director David Weild · Director Donald Foley · Director Jeffrey O'Donnell · Director Patrick Gallagher · Director Roy Tanaka · Director Seth Fischer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 27, 2018. Read the notice at the SEC .
equity, options SEC Nov 2017 $2 M Private placement after listing $2 to $10 million 2
BioSig Technologies, Inc.: Private sale, Nov 2017 × Investors in this round 2 investors had bought by the notice of Nov 17, 2017: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer Steve Chaussy · Executive Officer · Chief Financial Officer Andrew Filler · Director · Director David Weild · Director · Director Donald Foley · Director · Director Jeffrey O'Donnell · Director · Director Patrick Gallagher · Director · Director Roy Tanaka · Director · Director Seth Fischer · Director · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 17, 2017. Read the notice at the SEC .
equity, options SEC Apr 2017 $2 M Private placement after listing Under $2 million 22
BioSig Technologies, Inc.: Private sale, Apr 2017 × Investors in this round 22 investors had bought by the notice of Jul 20, 2017: 22 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $7 M offered; $5 M still to sell
Smallest investment taken $15,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kenneth Londoner · Executive Officer, Director · Chief Executive Officer and Director of the Issuer Steve Chaussy · Executive Officer · Chief Financial Officer David Weild · Director · Director Donald Foley · Director · Director Jeffrey O'Donnell · Director · Director Jerome Zeldis · Director · Director Patrick Gallagher · Director · Director Roy Tanaka · Director · Director Seth Fischer · Director · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “This represents aggregate consideration of $1,640,398 received in connection with the Issuer's closings occurring between April 6, 2017 and July 13, 2017.”Signed by Kenneth Londoner, Executive Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 20, 2017. Read the notice at the SEC .
equity, options SEC Oct 2015 $1 M No. 3 Under $2 million 14
BioSig Technologies, Inc.: Raise no. 3, Oct 2015 × Investors in this round 14 investors had bought by the notice of Nov 23, 2015: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $7 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $59,400
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Gregory Cash · Executive Officer, Director · President and Chief Executive Officer Steve Chaussy · Executive Officer · Chief Financial Officer David Foley · Director David Weild · Director Jeffrey O'Donnell · Director Jerome Zeldis · Director Kenneth Londoner · Director Patrick Gallagher · Director Roy Tanaka · Director Seth Fischer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in CA, CT, LA, MA, MI, MN, NJ, NY Remarks in the notice On the amounts: “This represents consideration of $325,000, $130,000 and $565,000 for the Issuer's first, second and third closing occurring on October 23, 2015, October 29, 2015 and November 18, 2015, respectively.”Signed by Gregory Cash, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 23, 2015. Read the notice at the SEC .
equity, options SEC Dec 2014 $4 M No. 2 $2 to $10 million 107
BioSig Technologies, Inc.: Raise no. 2, Dec 2014 × Investors in this round 107 investors had bought by the notice of Apr 3, 2015: 107 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $10 M offered; $6 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $481,080
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Gregory Cash · Executive Officer, Director · President and Chief Executive Officer Kenneth Londoner · Executive Officer, Director Steve Chaussy · Executive Officer · Chief Financial Officer Asher Holzer · Director Jeffrey O'Donnell · Director Jonathan Steinhouse · Director Patrick Gallagher · Director Roy Tanaka · Director Seth Fischer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in AR, CA, CT, DC, FL, GA, IL, IN, KS, LA, MA, ME, MI, NC, NE, NJ, OH, OK, PA, SC, TN, TX, VA, WV, and outside the US Remarks in the notice On fees: “The Issuer also issued five-year warrants to purchase a total of 400,900 shares of common stock at an exercise price of $3.75 per share to the placement agent as consideration for serving as the placement agent.”On the amounts: “This represents consideration of $339,500, $172,600,$1,071,000, $842,500, $557,500 and $1,025,900 for the Issuer's first, second, third, fourth, fifth and sixth closing, occurring on 12/19/14,12/30/14, 1/27/15, 2/10/15, 2/27/15 and 3/31/15 respectively.”Signed by Gregory Cash, President and Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Apr 3, 2015. Read the notice at the SEC .
equity, options SEC Feb 2013 $3 M No. 1 $2 to $10 million 41
BioSig Technologies, Inc.: Raise no. 1, Feb 2013 × Investors in this round 41 investors had bought by the notice of Jul 26, 2013: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for BioSig Technologies, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $166,860
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Asher S Holzer · Executive Officer, Director Budimir S Drakulic · Executive Officer, Director Kenneth Londoner · Executive Officer, Director Lora S Mikolaitis · Executive Officer Jeffrey S O'Donnell · Director Jonathan S Steinhouse · Director Kalyanam S Shivkumar · Director Roy S Tanaka · Director Seth S Fischer · Director William S Uglow · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in AR, CA, CO, CT, DE, FL, IA, IL, IN, KY, MA, NJ, NV, NY, OH, OK, PA, TX, WI, and outside the US Remarks in the notice On fees: “The Issuer also issued a five-year warrant to purchase 177,057 shares of common stock at an exercise price of $2.61 per share to the placement agent as consideration for serving as the placement agent.”On the amounts: “$600,000 of the amount sold represented conversion of outstanding indebtedness.”Signed by Kenneth Londoner, Chairman and Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Jul 26, 2013. Read the notice at the SEC .
equity, options SEC